PhRMA CEOs Express Grave Concern with the Inflation Reduction Act of 2022

 

A teaser image for PhRMA's Letter to Congress concerning the Inflation Reduction Act of 2022

PhRMA Member Company CEOs sent a letter urging Congress to reject the drug pricing provisions in the Inflation Reduction Act of 2022 and to instead work with all health care stakeholders on a balanced approach that delivers more affordable care for everyone and protects America’s global R&D leadership today and in the future.

A teaser image for PhRMA's Letter to Congress concerning the Inflation Reduction Act of 2022